TKNO · Alpha Teknova, Inc.
$8.90
-0.18 (-1.98%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$500.91M
Shares
53.69M
Volume · Sep 30
288.03K
Avg daily vol (3M)
217.59K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.90
Open$9.10
Day$8.78–9.20
52W close$1.99–9.33
Avg vol 30d236K
Short int1.6M · 2.9% float · 10.8d
Short vol43%
Last earningsAug 5, 2026
DataJun 2021–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$43.70M
Trailing 12 months
Net income (TTM)
−$16.77M
Trailing 12 months
Revenue growth YoY
+18.5%
Year over year
Operating margin
-36.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
+43.8%
Trailing year
Short interest
2.9%
Latest settlement · 10.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Teknova reported record Q2 2026 revenue of $12.2 million, up 18% year-over-year, and raised its full-year 2026 revenue guidance to $45–47 million (from $42–44 million) with improved free cash outflow expectations of less than $8 million.
Bullish
- + Q2 2026 revenue rose 18% YoY to a record $12.2 million, the highest quarterly revenue in company history
- + Company raised 2026 revenue guidance to $45–47 million (from $42–44 million), implying ~14% growth at midpoint vs. 6% prior
- + Improved 2026 free cash outflow outlook to less than $8 million for the full year
- + Q2 free cash outflow improved sharply to $0.6 million from $2.3 million YoY, the lowest since before the IPO
- + Gross margin expanded to 40.1% from 38.7% YoY on higher revenue
Bearish
- − Cell and gene therapy orders were the only major market to decline due to order timing and softer biotech funding flow-through
- − Net loss continued at $3.2 million (negative $0.06 per diluted share), though narrower than $3.6 million prior year
- − Full-year gross margin guided to mid-to-upper 30s%, below the 40.1% posted in Q2, citing prior-year favorable comparison
- − 2027 revenue outlook held unchanged at low $50 millions with no biotech funding tailwind embedded, delaying visibility
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+98%
above
Price vs 50-day avg
+28%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
94%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
+219%
trailing
YTD return
+134%
this year
Relative strength
+207%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.94% of float · ▲ +1.7% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+7%
Y/Y
Gross margin
33%
expanding
EPS growth
+44%
Y/Y
Free cash flow
$-9.8M
Balance sheet
$7.2M
net debt
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
fiscal year ending December 31, 2026
Total revenue
Initiated
$45M – $47M
prior FY $40.52M
midpoint +13.5% Y/Y
2026
Free Cash Outflow
Non-GAAP
up to $8M
Guided vs delivered
· last 3 settled
Total revenue
fiscal year ending December 31, 2024
guided $35M – $38M
$37.75M
In line
Total revenue
fiscal year ending December 31, 2023
guided $37M – $40M
$36.68M
Miss −4.7%
Total revenue
2022
guided $44M – $48M
$41.42M
Miss −10.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+98%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
94%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.94% of float · ▲ +1.7% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $9 · 94%
Range high $9
vs 200-day avg +98%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TKNO
this stock
Alpha Teknova, Inc.
|
$500.91M | +134.2% | +7.4% | — | 2.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TKNO | -0.3% | +25.7% | +219.0% | +24.0% | +134.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +0.3% | +25.6% | +206.8% | +24.5% | +122.4% |